Hart Robert G, Pearce Lesly A, Bakheet Majid F, Benavente Oscar R, Conwit Robin A, McClure Leslie A, Talbert Robert L, Anderson David C
Department of Medicine (Neurology), McMaster University, Hamilton, Ontario, Canada.
Biostatistics Consultant, Minot, North Dakota.
J Stroke Cerebrovasc Dis. 2014 Apr;23(4):618-24. doi: 10.1016/j.jstrokecerebrovasdis.2013.05.021. Epub 2013 Jun 22.
Among participants in the Secondary Prevention of Small Subcortical Strokes randomized trial, we sought to identify patients with high versus low rates of recurrent ischemic stroke and to assess effects of aggressive blood pressure control and dual antiplatelet therapy according to risk status.
Multivariable analyses of 3020 participants with recent magnetic resonance imaging-defined lacunar strokes followed for a mean of 3.7 years with 243 recurrent ischemic strokes.
Prior symptomatic lacunar stroke or transient ischemic attack (TIA) (hazard ratio [HR] 2.2, 95% confidence interval [CI] 1.6, 2.9), diabetes (HR 2.0, 95% CI 1.5, 2.5), black race (HR 1.7, 95% CI 1.3, 2.3), and male sex (HR 1.5, 95% CI 1.1, 1.9) were each independently predictive of recurrent ischemic stroke. Recurrent ischemic stroke occurred at a rate of 4.3% per year (95% CI 3.4, 5.5) in patients with prior symptomatic lacunar stroke or TIA (15% of the cohort), 3.1% per year (95% CI 2.6, 3.9) in those with more than 1 of the other 3 risk factors (27% of the cohort), and 1.3% per year (95% CI 1.0, 1.7) in those with 0-1 risk factors (58% of the cohort). There were no significant interactions between treatment effects and stroke risk status.
In this large, carefully followed cohort of patients with recent lacunar stroke and aggressive blood pressure management, prior symptomatic lacunar ischemia, diabetes, black race, and male sex independently predicted ischemic stroke recurrence. The effects of blood pressure targets and dual antiplatelet therapy were similar across the spectrum of independent risk factors and recurrence risk.
在小皮质下卒中二级预防随机试验的参与者中,我们试图识别复发性缺血性卒中发生率高和低的患者,并根据风险状态评估强化血压控制和双重抗血小板治疗的效果。
对3020名近期经磁共振成像确诊为腔隙性卒中的参与者进行多变量分析,平均随访3.7年,其中有243例复发性缺血性卒中。
既往有症状性腔隙性卒中或短暂性脑缺血发作(TIA)(风险比[HR]2.2,95%置信区间[CI]1.6,2.9)、糖尿病(HR 2.0,95%CI 1.5,2.5)、黑人种族(HR 1.7,95%CI 1.3,2.3)和男性(HR 1.5,95%CI 1.1,1.9)均独立预测复发性缺血性卒中。既往有症状性腔隙性卒中或TIA的患者(占队列的15%),复发性缺血性卒中的发生率为每年4.3%(95%CI 3.4,5.5);有其他3种风险因素中超过1种的患者(占队列的27%),发生率为每年3.1%(95%CI 2.6,3.9);有0 - 1种风险因素的患者(占队列的58%),发生率为每年1.3%(95%CI 1.0,1.7)。治疗效果与卒中风险状态之间无显著交互作用。
在这个大型、经过仔细随访的近期腔隙性卒中患者队列以及强化血压管理中,既往有症状性腔隙性缺血、糖尿病、黑人种族和男性独立预测缺血性卒中复发。在各种独立风险因素和复发风险范围内,血压目标和双重抗血小板治疗的效果相似。